Genetic Testing for Rare Diseases: A Systematic Review of Ethical Aspects

Judith Kruse1*, Regina Mueller2, Ali A. Aghdassi3, Markus M. Lerch4 and Sabine Salloch5

1Institute of Ethics and History of Medicine, University Medicine Greifswald, Greifswald, Germany, 2Institute of Ethics and History of Medicine, Medical Faculty, University Tübingen, Tübingen, Germany, 3Department of Medicine A, University Medicine Greifswald, Greifswald, Germany, 4LMU Munich University Hospital, Munich, Germany, 5Institute of Ethics, History and Philosophy of Medicine, Hannover Medical School, Hannover, Germany

Genetic testing is associated with many ethical challenges on the individual, organizational and macro level of health care systems. The provision of genetic testing for rare diseases in particular requires a full understanding of the complexity and multiplicity of related ethical aspects. This systematic review presents a detailed overview of ethical aspects relevant to genetic testing for rare diseases as discussed in the literature. The electronic databases Pubmed, Science Direct and Web of Science were searched, resulting in 55 relevant publications. From the latter, a total of 93 different ethical aspects were identified. These ethical aspects were structured into three main categories (process of testing, consequences of the test outcome and contextual challenges) and 20 subcategories highlighting the diversity and complexity of ethical aspects relevant to genetic testing for rare diseases. This review can serve as a starting point for the further in-depth investigation of particular ethical issues, the education of healthcare professionals regarding this matter and for informing international policy development on genetic testing for rare diseases.

Keywords: genetic testing, rare diseases, orphan diseases, genetic counselling, ethics

INTRODUCTION

Around 29 million people in the European Union (EU) (European Union, 2008), 30 million people in the Unites States of America (USA) (Global Genes, 2020) and around 400 million people worldwide are affected by one out of 5,000 to 8,000 different rare diseases (Global Genes, 2020). There is no uniform definition of rare diseases. A disease is considered as rare in the EU if it affects no more than 5 in 10,000 people (European Union, 2008), this definition will be adhered to in the following article. Half of the patients diagnosed with a rare disease are children and approximately 3% of newborns are affected by a rare disease (Global Genes, 2020; Eurordis, 2005). At least 80% of rare diseases have a genetic origin (Global Genes, 2020). This can mean either the involvement of one or several genes or chromosomal abnormalities. Often entire families or ethnic groups are affected due to the hereditary nature of the disease. However, rare diseases can be caused by de novo mutations affecting single individuals (Eurordis, 2005). Genetic and phenotypic variability add to the incomplete knowledge of rare diseases which complicates the process of diagnosis, leading to a diagnostic odyssey lasting an average of 8 years (Global Genes, 2020, Wright et al., 2018). This not only poses an immense strain and psychological distress on the patients and their families but also presents a serious challenge and burden to healthcare systems (Wright et al., 2018).

A precise molecular diagnosis is essential for the efficient handling of rare diseases in order to provide disease management and treatment options. In addition, it enables informed future
family planning decisions and the formation of supportive networks of individuals and families affected by rare diseases (European Union, 2008; Wright et al., 2018). Early and precise diagnoses help to reduce further invasive and expensive testing and the psychological stress associated with an unknown diagnosis (Liu et al., 2019; Soden et al., 2012). A genetic diagnosis might not only be of interest for symptomatic individuals but can also be beneficial as a screening procedure in the identification of carriers and asymptomatic individuals and, thus, contributes to the secondary prevention of both benign and malignant diseases (Pulst, 2000).

Advances in genetic testing, especially next generation sequencing technologies (NGS), have positively impacted the likelihood of obtaining a genetic diagnosis in a timely manner (Wright et al., 2018; Liu et al., 2019, Soden et al., 2012). However, genetic testing still requires proper counseling prior to testing in order to obtain informed consent, and after the test when the results are delivered (Soden et al., 2012; Liu et al., 2019). If not properly understood by the patient, the disclosure of genetic test results might lead to adverse reactions, such as heightened anxiety and unnecessary precautionary measures (Committee on Bioethics, 2001). A positive test result in an individual might also provide genetic information about relatives who have not given their direct consent to this information. This can lead to communication challenges and brings the medical professional disclosing the information and the receiving patient into an uncomfortable position (Pulst, 2000; Ellis et al., 2001; Gross, 2002).

The rapid technological advancements in genetics and the lack of education in this field limit the ability of many nonspecialized physicians to partake in the much needed professional discussion of ethical issues in genetic testing (Pulst, 2000). The widespread lack of experience with rare diseases often only intensifies this problem. Issues of particular relevance for rare diseases include the ethical justification of testing for a condition that does not have treatment options available, which is the case for many rare diseases, or the seemingly ubiquitous risk of receiving a result of unknown or ambivalent significance and the necessary measures to follow (Boycott et al., 2013; Warman Chardon et al., 2015; Petrikin et al., 2015). Less obvious issues also need thorough ethical discussion, such as counseling for postmortem genetic testing, which is most relevant in instances of sudden unexpected deaths (Working Group commissioned by the Ontario Genetic Testing Advisory Committee, 2016; Tester and Ackermann, 2017). Additionally, accessibility of genetic testing itself can bear ethical challenges when routine care laboratories do not provide the tests and research settings remain the only option. Laboratories often lack any interest in providing genetic testing, especially for extremely rare diseases, since these tests have a low volume and the development and validation can be expensive (Ledbetter and Faucett, 2008).

This review is the first, to the best of the authors’ knowledge, to present a profound overview of all ethical aspects of genetic testing for rare diseases as published in the literature. In systematizing ethical problems related to this field this review can assist researchers in the field of genetics as well as clinicians and counsellors in enhancing the moral sensibility for issues pertinent to their professional practice. For example, this review systematically gives a list of ethical issues occurring at the micro-level of patient-provider-contact and enables a further in-depth literature analysis of moral problems relevant for the individual reader. It furthermore provides a systematic basis for the ethical education of not only healthcare professionals but also patients, their families and other relevant stakeholders. This review provides a systematic background for further empirical and normative investigations of ethical aspects and is meant as a comprehensive aid to health policy making.

**MATERIALS & METHODS**

**Aim**

This article provides an overview of the full spectrum of ethical aspects in genetic testing for rare diseases based on a systematic review of the literature closely following the methodology used by Strech et al. (Strech et al., 2013). The reporting is in line with the PRISMA statement. The review does not aim to answer a specific normative-ethical question, but covers several ethical aspects related to genetic testing for rare diseases. The ethical aspects are qualitatively extracted from the publications and presented in a descriptive manner.

**Search Methods**

The electronic databases Pubmed, Science Direct and Web of Science were searched (see **Figure 1** for search strings and flow diagram). The results of each search were downloaded and duplicates discarded. The database searches were conducted in June 2020. Language restrictions for the search were English and German.

**Eligibility Criteria**

The only eligibility criterion for a publication to be included in the current systematic review was the description of an ethical aspect related to genetic testing for rare diseases.

“Rare diseases” are defined according to the EU as a disease affecting no more than 5 in 10,000 people (living in the EU) (European Union, 2008). Publications discussing rare diseases as a general topic were included as well as publications focusing on specific groups of rare diseases (e.g., neuromuscular disorders) or a single rare disease (e.g., Gaucher’s disease). Publications dealing exclusively with genetic screening, for example, newborn screening, were not included since this review focuses on predictive genetic testing rather than on population screening.

“Ethical aspects” were identified on the basis of the ethical theory of principlism, according to Beauchamp and Childress (Beauchamp & Childress, 2019). This approach defines four ethical principles: Respect for autonomy, non-maleficence, beneficence and justice. These four principles provide a general orientation and ought to be followed unless they conflict. If a conflict arises and not all principles can be followed, the conflicting principles need to be balanced in
order to reach a solution. This act of balancing is always performed in the light of the specific situation.

"Genetic testing" is defined as a laboratory examination aimed at detecting or ruling out the presence of hereditary illnesses or predisposition to such conditions in a person by directly or indirectly analyzing their genetic heritage (e.g., genes, chromosomes, proteins) (European Union, 1997).

Up until the completion of this article, no definite set of criteria had been established on how to conduct a quality appraisal for reviews of ethical literature (Mertz, 2019). Consequently, no quality appraisal was conducted in the present review. An inadequate quality appraisal might withhold valuable features because the intention of this review is to display the full spectrum of ethical aspects.

No restriction was applied to the type of publications included in this review. Therefore, not only original articles but also comments, editorials and book chapters were included. In order to display the full spectrum of ethical aspects relevant to the review question, not only argument-based but also empirical literature (when discussing ethical arguments) was included (See Figure 2 for publication types).

Similarly, no limit was established regarding the year of publication in order to include all ethical aspects mentioned and portray changes in the discussion over time.

**Study Selection**
A title/abstract screening was performed on all publications retrieved from the databases searched. If publications appeared
to meet the eligibility criteria, in a second step, the full text was analyzed. If a publication still met the criteria, i.e., addressed ethical aspects in the context of genetic testing for rare diseases, it was included in this review. After the inclusion of publications derived from the database search, an additional screening of all references and footnotes was conducted and supplementary publications were included based on the criteria described (see Figure 1 for search strings and flow diagram).

Extraction and Synthesis of Ethical Aspects
The data were analyzed according to qualitative content analysis, as proposed by Mayring (2014), using the software MAXQDA12. The publications were screened for relevant text passages which, in a first step, were each assigned a descriptive code. These codes were then grouped if they described the same ethical aspect. These inductively derived codes were grouped in deductive categories and subcategories. They were regularly revised and altered to eliminate doubling or overlap to ensure the reliability of the coding system and the categories. Regular team meetings were held to discuss the coding procedure with all authors. The latter have academic backgrounds in medicine, applied ethics and philosophy.

RESULTS
The electronic database searches resulted in 307 publications published between 1988 and 2020. A total of 135 articles were identified by title abstract screening and the full texts were thoroughly examined based on the inclusion criteria. Eventually, 38 publications were included for systematic review. An additional 17 publications were identified by screening the citations. Fifty-four of these publications are written in English and one is written in German (see Table 1 for the publications included; see Figure 2 for the types of publication).

A total of 918 relevant text passages were identified in the 55 publications included. These text passages were given descriptive codes, which were then pooled to a total of 93 different ethical aspects. These codes were grouped into three main categories: Process of testing, consequences of the test outcome and contextual challenges. A total of 20 subcategories were introduced within these main categories to structure the results further (see Table 2 for the coding system).

The following three main categories were established:

1) Process of testing: Ethical aspects concerning the procedure of genetic testing for rare diseases, the analysis of these tests and the delivery of the results to the patient and/or the family.
2) Consequences of the test outcome: Ethical aspects that result from the knowledge of the test result or the decisions made following the disclosure and patient reactions to the test result.
3) Contextual challenges: Ethical aspects that are associated with the circumstances and background of the tests, the diseases tested for and the test results.

Process of Testing
The category process of testing encompasses 36 ethical aspects in nine subcategories (see Table 2 for the coding system and Figure 3 for the categories and subcategories). These aspects most often relate to practical issues which are prominent in routine clinician-patient-interactions such as obtaining informed consent or interpreting the test results. Accessibility is a broadly discussed ethical issue starting with the necessary referral to a testing facility which, however, presupposes the suspicion of a rare genetic disorder and knowledge of the testing opportunities:

"However, primary care physicians should be increasingly alerted to the new diagnostic options.
for patients with rare, unclassified conditions who may benefit from NGS-based genetic testing, and refer such patients to a center of rare diseases or similar tertiary care facility.” (Lohmann and Klein, 2014)

A challenge is seen in finding local or even national laboratories providing adequate testing for rare diseases and especially ultra-rare diseases:

“...in contrast, for rare genetic conditions, testing may be available from very few laboratories, necessitating specimen and patient referrals across national boundaries.” (Cox et al., 2003)

Additionally, tests might be offered in research settings only, which further complicates the process of counselling:

“[...] some tests exist in a gray area between the research and clinical worlds, either temporarily because they are in transition, or permanently because there is no market for the test.” (Biesecker, 1996)

An inevitable component of genetic counselling is obtaining informed consent for the testing procedure and the disclosure of the results. In view of the rapidly evolving field of genetic technologies and the very specific characters of the genetic disorders the counsellor is confronted with major communicative challenges:

“[...] individualization may need to be integrated more into the informed consent process in order to accommodate individual preferences, allowing individuals the autonomy to opt in or out of receiving more extensive information regarding results.” (Danielsson et al., 2014)

The subcategory “timing of testing” is very prominent in the ethical literature included in the review. Several different time frames are discussed, including preimplantation of genetic testing, genetic testing during pregnancy, genetic testing in minors or testing for late onset diseases. These are especially sensitive topics about which patients might have preconceived notions which need to be respectfully addressed during counselling. Only post mortem genetic testing has not been prominently discussed even though coming with difficulties in obtaining consent and respect for the deceased.

**Consequences of the Test Outcome**

The category **consequences of the test outcome** consists of 37 ethical aspects in seven subcategories. It deals with aspects resulting directly from the disclosure of the outcome (see **Table 2** for the coding system and **Figure 3** for the categories and subcategories). This category is relevant for a wide range of health care professionals as it focuses on potentially far-reaching clinical consequences and has major implications for provider-patient-communication.

Some of the consequences of the test outcome were judged as **benefits**; others are rather negatively connoted. The positive aspects include the knowledge about the condition and its therapy. The diagnosis ideally leads to accessing treatment options but is sometimes viewed as insufficient if no direct treatment is available. This situation is challenging and should be anticipated in research and clinical practice:

“Even if we know the genes involved and the loci associated with the condition, this does not mean that we have an immediate specific line of treatment. This mismatch between risk information and the possibility of effective treatment is one of the sources of ethical, legal, and social conflicts with which researchers and clinicians should be familiar.” (Fuentes and Martin-Arribas, 2007)

But also less obvious options such as becoming part of a patient self-help group and connecting via social media with individuals and families with similar diagnoses might be the consequence of a molecular diagnosis:

“A diagnosis also provides the family an opportunity to connect with disease-specific support groups so that...
| Main category                   | Sub-category                   | Ethical aspect                          | Number of occurrences | References |
|--------------------------------|-------------------------------|-----------------------------------------|-----------------------|------------|
| Process of testing             | Availability                  |                                         | 402                   |            |
|                                | Collaboration of laboratories/specialists |                                         | 73                    |            |
|                                | Access to genetic testing     |                                         |                       |            |
|                                | Research laboratories         |                                         | 10                    | (23) (24) (32) (34) (44) (53) |
|                                | Clinical laboratories         |                                         | 10                    | (1) (16) (23) (24) (28) (32) (39) (53) |
|                                | Direct to consumer testing    |                                         | 43                    | (3) (20) (24) (30) (32) (33) (36) (38) (41) (42) (44) (49) (50) (53) |
| Consent                        | Informed consent process      |                                         | 52                    | (2) (9) (12) (15) (16) (18) (19) (20) (22) (26) (31) (33) (36) (38) (39) (41) (47) (50) (54) |
|                                | Consent with minors           |                                         | 3                     | (47) (49) (55) |
|                                | The right to know             |                                         | 4                     | (13) (19) (28) (54) |
|                                | The right not to know         |                                         | 5                     | (2) (8) (9) (21) (54) |
|                                | Tiered or dynamic forms of consent |                                         | 1                     | (2)         |
| Genetic counseling             | Difficulties of counseling    |                                         | 48                    | (1) (21) (32) (34) (37) (50) (54) |
|                                | Requirements                  |                                         | 12                    | (1) (16) (19) (21) (28) (31) (33) (36) (37) (44) |
|                                | Retrospective counseling      |                                         | 3                     | (48) (51) |
|                                | Importance of genetic counseling |                                         | 3                     | (9) (50) |
| Timing of testing              | Testing minors                |                                         | 7                     | (4) (25) (31) (47) (49) |
|                                | Relevance of timing           |                                         | 5                     | (6) (7) (13) (49) (55) |
|                                | Preimplantation genetic testing |                                         | 34                    | (25) (27) (49) (47) (54) |
|                                | Testing for late-onset diseases |                                         | 21                    | (19) (26) (31) (40) (41) (43) (47) (54) (55) |
|                                | Postmortem genetic testing    |                                         | 6                     | (9) (16) (17) (25) (27) (40) (47) (54) |
| Interpretation of results      | Interpretation                |                                         | 28                    | (9) (12) (19) (20) (26) (31) (32) (33) (50) |
|                                | Consequences of inaccurate interpretation |                                         | 15                    | (17) (19) (26) (29) (33) (41) (47) |
| Regulations and standards      | Laboratory practice issues    |                                         | 56                    | (24) (44) (49) (53) |
|                                | Patient management issues     |                                         | 17                    | (44)       |
|                                | Need for standards            |                                         | 13                    | (24) (28) (40) (44) (53) |
|                                | Patient/family as decision-maker |                                         | 6                     | (40) (48) (54) (55) |
|                                | Protection from unethical practices |                                         | 4                     | (20) (40) (53) |
|                                | Regulations creating barriers |                                         | 9                     | (40)       |
| Physicians                     | Increased demands on physicians |                                         | 22                    | (1) (7) (20) (24) (28) (29) (30) (31) (36) (37) (49) |
|                                | Family-professional collaboration |                                         | 17                    | (23) (24) |
| Reasons for testing            | Clinical suspicion            |                                         | 30                    | (8) (22) (33) |
|                                | Desire to offer proper care   |                                         | 10                    | (1) (8) (14) (22) (31) (54) |
|                                | The need to know              |                                         | 9                     | (5) (22) (53) |
|                                | Reproductive choice           |                                         | 4                     | (1) (22) (47) (54) |
| Other                          | Disclosure and access to the results |                                         | 20                    | (2) (9) (26) (31) (33) (46) (54) |
|                                | Reasons not to test           |                                         | 14                    | (2) (9) (26) (31) (33) (46) (54) |
| Consequences of the test outcome | Diagnosis                    |                                         | 384                   | (15) (6) (7) (10) (11) (17) (20) (23) (24) (29) (30) (34) |
|                                | End of diagnostic odyssey     |                                         | 78                    | (3) (6) (7) (10) (11) (17) (20) (23) (24) (29) (30) (34) (38) (47) (49) (50) |
|                                | Diagnostic certainty          |                                         | 31                    | (3) (7) (8) (9) (10) (11) (14) (15) (19) (20) (24) (25) (28) (31) (34) (38) (47) (49) (50) |
|                                | Prognosis                     |                                         | 7                     | (7) (10) (15) (24) (31) (41) (51) |
|                                | Opportunities as a result of receiving diagnosis |                                         | 12                    | (5) (7) (10) (14) (15) (23) (24) (34) (37) |
|                                | Not receiving a molecular diagnosis |                                         | 11                    | (17) (30) (33) (34) |
|                                | Positive effects of DNA diagnosis |                                         | 1                     | (51)       |
|                                | Social, personal and medical impacts of diagnosis |                                         | 1                     | (3)       |
| Actionability of results       | Access to disease-specific services |                                         | 81                    | (15) (23) (24) (34) (54) |
|                                | Variants of unknown significance |                                         | 5                     | (3) (9) (17) (19) |
|                                | Testing in the absence of therapeutic benefits |                                         | 10                    | (6) (30) (32) (36) (49) (54) |
|                                | Prevention/amelioration of disease and suffering |                                         | 25                    | (1) (2) (6) (10) (13) (15) (19) (20) (25) (29) (34) (40) (47) (48) (50) (51) |
|                                | Disease management, therapy and interventions |                                         | 30                    | (2) (3) (6) (10) (19) (24) (26) (29) (33) (34) (38) (41) (52) |

(Continued on following page)
| Main category | Sub-category | Ethical aspect | Number of occurrences | References |
|---------------|-------------|----------------|-----------------------|------------|
| Incidental findings | Handling of incidental findings | 14 | (3) (4) (7) (17) (19) (22) (24) (26) (31) (32) (36) (42) (49) |
| | Consequences of incidental findings | 8 | (4) (17) (26) (31) (42) (49) |
| | Consenting to receive incidental findings | 8 | (4) (17) (26) (32) (49) |
| | Incidental findings in children | 6 | (7) (22) (28) |
| | Reporting recommendations | 13 | (7) (16) (17) (19) (26) (31) (32) |
| | Measures to decrease incidental findings | 3 | (10) (17) (31) |
| | Controversy: Proactively searching for unsolicited information | 1 | (7) |
| Stigma and discrimination | Impact of stigma and discrimination | 41 | (1) (2) (3) (8) (9) (28) (33) (38) |
| | Legislation to address discrimination | 8 | (26) (41) |
| | Discrimination by insurance companies | 7 | (21) (40) (41) (49) (50) |
| | Discrimination at the workplace | 8 | (21) (41) (50) (52) |
| | Adoption agencies/child welfare institutions | 3 | (52) (55) |
| | Other types of stigma and discrimination | 11 | (3) (31) (35) (40) (47) (52) |
| | Genetic testing used against people | 1 | (31) |
| Family planning | Informed decision-making | 17 | (1) (2) (3) (8) (10) (24) (27) (34) (42) (50) (52) |
| | Abortion/Termination | 35 | (1) (8) (10) (12) (13) (14) (18) (25) (27) (31) (35) (41) (46) (50) (51) |
| | Implications for future pregnancies | 6 | (1) (8) (31) |
| | Social consequences of private reproductive decisions | 1 | (40) |
| Involvement of relatives | Information about people not directly tested | 4 | (2) (9) (36) (49) |
| | Relevance of results to family members/others | 17 | (6) (5) (9) (11) (26) (28) (33) (36) (42) (46) (49) (50) (64) |
| | Disclosure to family | 14 | (2) (5) (9) (26) (28) (33) (41) (46) (49) (54) |
| | Paternal rights | 6 | (12) (18) |
| Other | Uncertainty due to implications of the test result | 8 | (1) (36) (37) (46) (54) |
| | Awareness of disease | 4 | (8) (21) (34) |
| | Distress and adverse effects | 19 | (1) (3) (4) (5) (9) (22) (33) (34) (36) (47) (55) |
| Contextual challenges | Increased pressure to test | 9 | (1) (14) (34) (40) (53) |
| | Coerced testing | 4 | (12) (25) (33) (49) |
| | Routinization of test usage | 3 | (12) (18) (27) |
| | Testing is optional | 1 | (6) |
| | Pressure to test in order to eradicate disease | 1 | (54) |
| Economic aspects | Commercial interests restricting testing | 9 | (1) (14) (34) (40) (53) |
| | Dilemma if expensive test is used for information only | 2 | (14) |
| | Cost saving by genetic testing | 16 | (3) (6) (10) (13) (15) (19) (34) (40) (51) |
| | Genetic testing is expensive | 7 | (12) (14) (35) (40) (48) (53) |
| | Patents | 3 | (45) |
| | Large number of disorders is a cost challenge | 1 | (14) |
| | Difficulties to obtain funding | 2 | (15) (20) |
| Data | Infrastructural challenges | 7 | (2) (26) (41) (49) |
| | Privacy concerns | 11 | (26) (33) (41) (46) (50) (54) |
| | Third parties using the data | 2 | (41) (49) |
| | Data sharing | 4 | (23) (26) |
| Other | Rarity as a challenge | 7 | (12) (32) (34) (63) |
| | Difficulties in test development | 8 | (20) (31) (53) |
| | Cultural differences | 7 | (1) (18) (48) |
| | Public understanding of genetic testing and rare diseases | 10 | (1) (27) (31) (40) (48) |
| | Effects on people living with a disability | 6 | (1) (18) (27) (40) |
| | Other ethical dilemmas | 21 | (1) (7) (8) (12) (15) (19) (20) (26) (31) (40) (41) (46) (53) |
they might meet others affected by the same rare disorder and exchange information about useful therapies and educational strategies." (Kingsmore et al., 2011)

This community aspect is particularly relevant in situations where no conventional treatment options are available. In this case interprofessional care plays a prominent role as an increased coordination of care among providers will become necessary to provide best supportive care.

Further ethical issues involve the relevance of the test result for people who are not directly tested. By disclosure of their results the family members learn of very private information about themselves (and further relatives) which they did not consent to but if not disclosed might have an interest to know. This ambiguous situation needs to be extensively addressed and prepared for during counselling:

“Ethical challenges are generated when information produced by the results may affect third parties, including family members not directly involved in the process.” (Fuentes and Martín-Arribas, 2007)

**Contextual Challenges**

The category contextual challenges includes 21 ethical aspects in four subcategories (see Table 2 for the coding system and Figure 3 for the categories and subcategories). These aspects do not refer directly to the procedure or result of the test but
rather address the general circumstances of genetic testing for rare diseases, including societal aspects. In this, the contextual aspects typically lie out of the direct sphere of influence of clinicians and genetic counsellors but touch more generally on health care structures, policies and frameworks.

For example, it is argued, that it is inevitable to be aware of contextual challenges in order to integrate patients’ experiences and expectations into appropriate support and care. Optimal research and care, however, are often hindered by the contingent character of rare diseases:

“The application of evidence-based medicine in the field of genetic testing often remains questionable, because rare diseases imply a difficulty to meet the criteria required in terms of sample size for clinical trials or sound genetic research.” (Fuentes and Martín-Arribas, 2007)

Further ethical issues extend to economic aspects influencing the provision and development of genetic tests for rare diseases. Depending of the point of view genetic testing for rare diseases can be very cost effective as in cutting back the diagnostic odyssey of many years but are, as a single test, often still expensive. Here societal dialogue is necessary to examine the costs and benefits not only for the individual patient but also the society as a whole. On a macro level the financing of healthcare systems prominently intersects with the provision of care:

“Patients with rare diseases traditionally experience a prolonged and expensive diagnostic odyssey culminating in a delayed diagnosis or, frequently, no diagnosis at all. […] this diagnostic odyssey is a financial burden to the health-care system, costing more than US $10,000 per patient.” (Marshall et al., 2019)

An aspect commonly brought up in the economic discussion is the question of testing without consequences, when the test is used for information purposes only. This leads to delicate situations in clinical care, for example, when such a testing is performed during pregnancy:

“The expected increased uptake of NIPD [non-invasive prenatal diagnosis] […] highlight the ethical issues associated with using NIPD for information only and the appropriateness of directing resources to a test that would not change pregnancy management […]. Decisions about how NIPD is offered will need to take this concern into consideration, keeping in mind […] the clinical and psychological benefits afforded by NIPD which include early the possibility of reassurance or provision of information for planning and preparation of the birth of an affected child, as well as the potential of access to surgical termination of pregnancy.” (Verhoef et al., 2016)

The contextual challenges of genetic testing for rare diseases eventually include different ethical fields such as the methodology of clinical trials, issues of distributional justice and dealing with diagnoses without appropriate treatment options.

Some shifts in the perspectives of the discussion of ethical aspects over the past 30 years are visible within the coding system.
(See Figure 4 Years of publication and ethical aspects). Literature published in the 1990s and early 2000s focuses more on practical aspects, such as regulation and standards concerning laboratory practices (Terrenoire, 1992; Biesecker, 1996; Pulst, 2000; Cox et al., 2003). At that time, the establishment of guidelines was essential to address appropriately the rapidly developing technologies. Additionally, uncertainties about the possible impacts of the fast rising usage of genetic testing technologies were widely prevalent. Possible scenarios of discrimination resulting from the disclosure of a genetic test result were brought up (Thomas, 1999; Gin, 1997; Committee on Bioethics, 2001; Thomas, 2004) and the handling and security of genetic data was reflected (Terrenoire, 1992; Thomas, 1999; Pulst, 2000; Gross, 2002; Thomas, 2004). Interestingly, data management and security remained important issues to this day but have left the center of the debate (Cox et al., 2003; Umbach et al., 2020). The perspectives of more recent publications, in alignment with advancements in genetic testing such as whole genome sequencing, have shifted to more specific questions, such as the handling of incidental findings (Marshall et al., 2019; Houdayer et al., 2019; Umbach et al., 2020). The obtainment of incidental findings is closely related to the establishment of new technologies (Umbach et al., 2020). This raises questions regarding their utility, consent and, thereby, aggravates the appropriate delivery of results (Umbach et al., 2020). Similarly, the indispensable role of the physician in interpreting and disclosing the results (Nguyen and Charlebois, 2015; Hayeems and Boycott, 2018; Zhytnik et al., 2020) and their relationship to the patient (Lohmann and Klein, 2014; Might and Wilsey, 2014) have gained significance in the literature.

**DISCUSSION**

The appropriate handling of ethical issues is a requisite for adequate care in patients undergoing genetic testing for rare diseases. A variety of publications, using different methods and focal points, dealing with a multiplicity of ethical aspects were identified in this review. Positive, negative and ambiguous aspects were found which portray the challenges with which individuals, families, professionals, healthcare systems and society are faced. A thorough understanding of their diversity and complexity is a prerequisite for attending to ethical aspects systematically and transparently. In the light of the diversity of ethical issues one aspect from each major coding category will be discussed exemplarily in the following while also highlighting the intersection with other relevant ethical aspects.

**Process of Testing**

An aspect which was discussed most controversially in the literature published in the recent 10 years and which is of particular relevance to rare diseases, in contrast to more common diseases, is the availability and accessibility of genetic testing. Genetic testing specifically in the research setting was intensively discussed by various authors (Biesecker, 1996; Fuentes and Martin-Arribas, 2007; Marshall et al., 2019). Many patients with a suspected rare disease find themselves in a situation where their only access to a genetic test is to be found in a study context, since many genetic tests for rare diseases are unattractive to clinical laboratories for their low profitability (Biesecker, 1996; Thomas, 2004; Marshall et al., 2019).

Missing opportunities to undergo a genetic test outside the research setting might compromise the key ethical requirement of voluntary participation in research. In addition, other regulations apply to research laboratories than to clinical laboratories (Biesecker, 1996; Pulst, 2000; Might and Wilsey, 2014). Standards for test validity and reliability differ from those in clinical laboratories, further complicating patient communication and the utilization of results (Biesecker, 1996; Danielsson et al., 2014). Also standards for the return of results vary, patients often receive the results only after completion of the study, while appropriate counseling is not always guaranteed (Krajewski and Shy, 2004; Danielsson et al., 2014; Might and Wilsey, 2014). This leaves the referring physician with a particularly difficult task of navigating this very specific setting with their patient and the family.

The intersection between clinical care and study context is only superficially addressed in national and international policies. One example is “The Council of Europe Convention on Human Rights and Biomedicine” which also covers genetic testing. Article 12 of the Convention limits the usage of predictive genetic testing to that it “[…] may be performed only for health purposes or for scientific research linked to health purposes […]” (European Union, 1997). Thereby, genetic testing in research setting is technically covered by the convention as a minimum standard but no elaboration is offered concerning this specific situation. Furthermore, as of June 2020 this convention has only been ratified by 29 members of the European Council (Tester and Ackermann, 2017).

**Consequences of the Test Outcome**

One frequently discussed outcome of genetic testing is the possibility of facing stigma and discrimination (Korf and Rehm, 2013; Dimichele et al., 2006; Tester and Ackermann, 2017). According to the definition of E. Goffman a stigma describes a distinctive feature of a person which is linked to a negative stereotype and is considered “deeply discrediting” by societal standards (Goffman, 1963). Stigma and discrimination might come in a multitude of forms such as regulatory issues regarding insurance or employment or social issues such as exclusion from social activities (Williams et al., 2010; Tester and Ackerman, 2011). Stigmatization can apply not only to people affected by a diagnosis, but also those with a positive carrier status. In specific cultural contexts this stigmatization could cause gender specific discrimination and reproductive restrictions for some women (Zhytnik et al., 2020). In the United States, as an example, in 2009 the Genetic Information Nondiscrimination Act (GINA) was signed which protects patients from being denied employment and health insurance based on their genetic test results (Tester and
et al., 2015). This menace of stigmatization and discrimination raises the questions, who should have access to genetic information and how to best ensure confidentiality and data protection while still utilizing the test results to their full potential (Umbach et al., 2020).

One aspect which was not represented in this review is that stigma and genetic discrimination are not universal experiences for everyone diagnosed with a genetic disease but highly individual experiences which might even have differing outcomes (Williams et al., 2010). A genetic cause is not automatically connected to a sense of being stigmatized (Sankar et al., 2006). A hereditary disease might also mean growing up among people with the same condition and impairments. Therefore, a genetic diagnosis might become a positive feature of identity, as for example being the basis for family cohesiveness, or as a link to one's ancestry (Sankar et al., 2006).

Additionally, a diagnosis might also imply a connection to other affected individuals outside the family which can be accessed locally in the form of support groups or globally in online supportive networks (Kingsmore et al., 2011; Petrikin et al., 2015). Useful information about the condition, potential treatment options or supportive services can be exchanged alleviating the commonly sparse information available about genetic conditions. Even other forms of support such as psychological or spiritual assistance will be easier to access once the condition and prognosis are clear (Petrikin et al., 2015). This can be especially beneficial in situations where a diagnosis does not come along with curative therapeutic options.

**Contextual Challenges**

Unexpectedly, not one of the publications included has economics aspects as its main focus. Of the publications included, 17 discuss an economic aspect but only four publications include two or more aspects. The reason for this neglect of economic aspects remains rather unclear. The EU and several individual states have legislations in place to foster the research on medicinal products for rare diseases as well as the provision of those (European Union, 2008). These legislations do not include medical devices such as genetic tests (European Union, 2008). Therefore, laboratories are not provided with an economic incentive for developing such tests (Hayeems and Boycott, 2018). Some of the authors voiced concern about the exclusivity of patents on genes and how they contribute significantly to the high prices of genetic tests for rare diseases (Nguyen and Charlebois, 2015). Thereby, the tests become even less attractive to clinical laboratories, perpetuating the testing in research laboratories discussed later (Nguyen and Charlebois, 2015). Patented genes offer the owner a monopoly not only of the initial diagnostic test but every diagnostic method using the same DNA sequence (Might and Wilsey, 2014). Thereby, the already difficult access to testing is at risk of being further compromised on behalf of patent interests.

**Limitations**

This review aims to offer an empirical analysis portraying the diversity and complexity of ethical aspects relevant to genetic testing for rare diseases. The purpose of this review was not to quantify how often certain ethical aspects have been mentioned in the literature. Furthermore, it is important to understand that the frequency with which an ethical aspect occurs does not necessarily correlate to its relevance or importance. The ethical aspects displayed in this review are limited to the publications found via the three databases accessed (Pubmed, Science Direct, Web of Science). Prior to the final search, an exploratory search of several databases was conducted and the three databases subsequently accessed were identified as delivering the highest number of relevant results. Additionally, the neglect of literature written in languages other than English or German limits this review.

No quality appraisal for the included literature was performed due to the lack of quality assessment tools for systematic reviews of ethical literature (Mertz, 2019). Therefore, all publications fitting the inclusion criteria were included and it is up to the readership to critically judge the quality of the ethical aspects presented.

**CONCLUSION**

A lack of knowledge and comprehension of the fast-paced developments of genetic testing among professionals poses an obstacle to accessing comprehensive testing (Nguyen and Charlebois, 2015). Many physicians find themselves insufficiently equipped for processing the amount of information that accompanies a genetic testing result for a rare disease and feel overwhelmed when navigating the complex ethical aspects associated (Pulst, 2000; Sankar et al., 2006; Soden et al., 2012). This is only intensified by the diversity of rare diseases themselves and the widespread lack of knowledge and awareness about them, and needs to be addressed (Soden et al., 2012).

This review found that not many physicians find themselves in a position where they feel knowledgeable enough to order and conduct genetic testing, especially for rare diseases (Soden et al., 2012). An effective cooperation with genetic counsellors forms the basis to solving this issue. These counsellors are specially trained non-physician experts in genetics who should be an integral part of every inter-professional genetics team (Soden et al., 2012; Boycott et al., 2013; Fuentes and Martín-Arribas, 2007).

However, this should, on the other hand, not deviate from the much needed extension of the education of physicians and other healthcare professionals to deliberately cover the advantages and disadvantages of genetic testing in the context of rare diseases, including not only medical subjects but also the ethical and legal issues presented in this review (Gin, 1997; Soden et al., 2012; Umbach et al., 2020).

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
AUTHOR CONTRIBUTIONS

JK, SS, and RM developed the research question; JK and RM did the data collection; SS, JK, RM, AA, and ML contributed analytic tools and data analysis; JK drafted the article. All authors revised the article. All authors read and approved the final article.

REFERENCES

Beauchamp, T. L., and Childress, J. F. (2019). Principles of Biomedical Ethics. 8th edn.. Oxford: Oxford University Press.
Bieseker, L. G. (1996). Orphan Tests. Camb Q. Healthc. Ethics 5 (2), 300–306. doi:10.1017/s0963180100007076
Boycott, K. M., Vanstone, M. R., Bulman, D. E., and MacKenzie, A. E. (2013). Rare disease Genetics in the Era of Next-Generation Sequencing: Discovery to Translation. Nat. Rev. Genet. 14 (10), 681–691. doi:10.1038/nrg3555
Committee on Bioethics (2001). Ethical Issues with Genetic Testing in Pediatrics. Pediatrics 107, 1451–1455. doi:10.1542/peds.107.6.1451

FUNDING

This work was supported by the European Union (grant numbers ESF/14-BM-A55-0050/16, ESF/14-BM-A55-0045/16 and ESF/14-BM-A55-0008/18). (http://www.esf.de/portal/EN/Home/home.html).

Diseases of Childhood by Next-Generation Sequencing. Expert Rev. Mol. Diagn. 11 (8), 855–868. doi:10.1586/erm.11.70
Korf, B. R., and Rehm, H. L. (2013). New Approaches to Molecular Diagnosis. JAMA 309 (14), 15114–15121. doi:10.1001/jama.2013.3229
Krajewski, K. M., and Shy, M. E. (2004). Genetic Testing in Neuromuscular Disease. Neurol. Clin. 22 (3), 481–508. doi:10.1016/j.ncl.2004.03.003
Ledbetter, D. H., and Fautcett, W. A. (2008). Issues in Genetic Testing for Ultra-rare Diseases: Background and Introduction. Genet. Med. 10 (5), 309–313. doi:10.1097/gim.0b013e3181729d99
Liu, Z., Zhu, L., Roberts, R., and Tong, W. (2019). Toward Clinical Implementation of Next-Generation Sequencing-Based Genetic Testing in Rare Diseases: Where Are We? Trends Genet. 35 (11), 852–867. doi:10.1016/j.tig.2019.08.006
Lohmann, K., and Klein, C. (2014). Next Generation Sequencing and the Future of Genetic Diagnosis. Neurotherapeutics 11 (4), 699–707. doi:10.1007/s41346-014-0288-8
Marshall, D. A., MacDonald, K. V., Heidenreich, S., Hartley, T., Bernier, F. P., Gillespie, M. K., et al. (2019). The Value of Diagnostic Testing for Parents of Children with Rare Genetic Diseases. Genet. Med. 21 (12), 2798–2806. doi:10.1038/s41436-019-0583-1
Mayring, P. (2014). Qualitative Content Analysis: Theoretical Foundation, Basic Procedures and Software Solution. Available at: https://nbn-resolving.org/urn: nbn:de:0168-ssoar-395173.
Mertz, M. (2019). How to Tackle the Conundrum of Quality Appraisal in Systematic Reviews of Normative Literature/information? Analysing the Problems of Three Possible Strategies (Translation of a German Paper). BMC Med. Ethics 20 (1), 81. doi:10.1186/s12910-019-0423-5
Might, M., and Wilsey, M. (2014). The Shifting Model in Clinical Diagnostics: How Next-Generation Sequencing and Families Are Altering the Way Rare Diseases Are Discovered, Studied, and Treated. Genet. Med. 16 (10), 736–737. doi:10.1038/gim.2014.23
Nguyen, M. T., and Charlebois, K. (2015). The Clinical Utility of Whole-exome Sequencing in the Context of Rare Diseases - the Changing Tides of Medical Practice. Clin. Genet. 88 (4), 313–319. doi:10.1111/cge.12546
Petrikin, J. E., Willig, L. K., Smith, L. D., and Kingsmore, S. F. (2015). Rapid Whole Genome Sequencing and Precision Neontology. Semin. Perinatology 39 (8), 623–631. doi:10.1053/j.semperi.2015.09.009
Pulst, S. M. (2000). Ethical Issues in DNA Testing. Muscle Nerve 23 (10), 1503–1507. doi:10.1097/00005850-200010000-00003
Sankar, P., Cho, M. K., Wolpe, P. R., and Schairer, C. (2006). What Is in a Cause? Exploring the Relationship between Genetic Cause and Felt Stigma. Genet. Med. 8 (1), 33–42. doi:10.1097/gim.01008984.67756.8b
Soden, S. E., Farrow, E. G., Saunders, C. I., and Lantos, J. D. (2012). Genomic Medicine: Evolving Science, Evolving Ethics. Personalized Med. 9 (5), 523–528. doi:10.2217/pme.12.56
Streich, D., Mertz, M., Knüppel, H., Neitzke, G., and Schmidhuber, M. (2013). The Full Spectrum of Ethical Issues in Dementia Care: Systematic Qualitative Review. Br. J. Psychiatry 202 (6), 400–406. doi:10.1192/bjp.bp.112.116335
Terrenoore, G. (1992). Huntington’s Disease and the Ethics of Genetic Prediction. J. Med. Ethics 18, 79–85. doi:10.1136/jme.18.2.79
Tester, D. J., and Ackerman, M. J. (2017). Evaluating the Survivor or the Relatives of Those Who Do Not Survive: the Role of Genetic Testing. Cardiol. Young 27, S19–S24. doi:10.1177/10479511166002183
Tester, D. J., and Ackerman, M. J. (2011). Genetic Testing for Potentially Lethal, Highly Treatable Inherited Cardiomyopathies/channelopathies in Clinical Practice. Circulation 123 (9), 1021–1037. doi:10.1161/ circulationaha.109.914838

Global Genes (2020). Rare Facts. Available at: https://globalgenes.org/rare-facts/ (Accessed June 1, 2020).
Goffman, E. (1963). Stigma: Notes on the Management of Spoiled Identity. Englewood Cliffs, NJ: Prentice-Hall.
Gross, M. L. (2002). Ethics, Policy, and Rare Genetic Disorders: the Case of Gaucher Disease in Israel. Theor. Med. Bioeth. 23 (2), 151–170. doi:10.1023/a:1020324336260
Hayeems, R. Z., and Boycott, K. M. (2018). Genome-wide Sequencing Technologies: a Primer for Paediatricians. Paediatr. Child Health 23 (3), 191–197. doi:10.1039/c8pp00152
Houdayer, F., Putois, O., Babonneau, M. L., Chaumet, H., Joly, L., Juif, C., et al. (2019). Secondary Findings from Next Generation Sequencing: Psychological and Ethical Issues. Family and Patient Perspectives. Eur. J. Med. Genet. 62 (10), 103711. doi:10.1016/j.ejmg.2019.103711
Kingsmore, S. F., Dinwiddie, D. L., Miller, N. A., Soden, S. E., and Saunders, C. J. (2011). Adopting Orphans: Comprehensive Genetic Testing of Mendelian
Thomas, S. M. (1999). Genomics: the Implications for Ethics and Education. Br. Med. Bull. 55 (2), 429–445. doi:10.1258/0007142991902358
Thomas, S. (2004). Society and Ethics f the Genetics of Disease. Curr. Opin. Genet. Development 14 (3), 287–291. doi:10.1016/j.gde.2004.04.014
Umbach, N., Beißbarth, T., Bleckmann, A., Dutte, G., Flatau, L., König, A., et al. (2020). Clinical Application of Genomic High-Throughput Data: Infrastructural, Ethical, Legal and Psychosocial Aspects. Eur. Neuropsychopharmacol. 31, 1–15. doi:10.1016/j.euroneuro.2019.09.008
Verhoef, T. I., Hill, M., Drury, S., Mason, S., Jenkins, L., Morris, S., et al. (2016). Non-invasive Prenatal Diagnosis (NIPD) for Single Gene Disorders: Cost Analysis of NIPD and Invasive Testing Pathways. Prenat Diagn. 36 (7), 636–642. doi:10.1002/pd.4832
Warman Chardon, J., Beaulieu, C., Hartley, T., Boycott, K. M., and Dyment, D. A. (2015). Axons to Exons: the Molecular Diagnosis of Rare Neurological Diseases by Next-Generation Sequencing. Curr. Neurol. Neurosci. Rep. 15 (9), 64. doi:10.1007/s11910-015-0584-7
Williams, J. K., Erwin, C., Juhl, A. R., Mengeling, M., Bombard, Y., Hayden, M. R., et al. (2010). In Their Own Words: Reports of Stigma and Genetic Discrimination by People at Risk for Huntington Disease in the International RESPOND-HD Study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B (6), 1150–1159. doi:10.1002/ajmg.b.31080
Working Group commissioned by the Ontario Genetic Testing Advisory Committee (2016). Use of Genome Wide Sequencing for Undiagnosed Rare Genetic Disease in Ontario. Available at: http://www.health.gov.on.ca/en/pro/programs/gtac/docs/gtac_report_use_of_gws_for_undiagnosed_rare_genetic_diseases.pdf.
Wright, C. F., FitzPatrick, D. R., and Firth, H. V. (2018). Paediatric Genomics: Diagnosing Rare Disease in Children. Nat. Rev. Genet. 19 (5), 253–268. doi:10.1038/nrg.2017.116
Zhytnik, L., Simm, K., Salumets, A., Peters, M., Martson, A., and Maasalu, K. (2020). Reproductive Options for Families at Risk of Osteogenesis Imperfecta: a Review. Orphanet J. Rare Dis. 15 (1), 128. doi:10.1186/s13023-020-01404-w

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Kruse, Mueller, Aghdassi, Lerch and Salloch. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.